



E-Mail: [greg@indegliacarney.com](mailto:greg@indegliacarney.com)

March 25, 2016

OTC Markets Group Inc.  
304 Hudson Street, Second Floor  
New York, NY 10013

**Re: Attorney Letter with Respect to Adequate Current  
Information of Harvey Westbury Corp. ("HVVW")**

Dear Sir or Madam:

We have been retained by Harvey Westbury Corp., a Wyoming corporation (the "Company" or the "Issuer"), for the purpose of rendering our opinion as to the adequacy of the current information and disclosure document posted by the Company on the OTC Disclosure and News Service and for other related matters. OTC Markets Group Inc. is entitled to rely on this opinion in determining whether the Issuer has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933, as amended (the "Securities Act"). We also confirm that counsel is a U.S. resident.

In connection with this rendering of this opinion, we have examined such corporate records and other documents and such questions of law as counsel considered necessary or appropriate for purposes of rendering this letter. We are authorized to practice law in the State of California and the State of New York. We are permitted to practice before the Securities and Exchange Commission (the "SEC") and have not been prohibited from practice thereunder.

We express no opinion with respect to laws of any jurisdiction other than the federal laws of the United States of America. This opinion is limited to the effect of the present state of the laws the United States of America.

As to matters of fact, we rely on information obtained from public officials, officers of the Issuer and other sources, where such sources are believed to be reliable. In rendering this opinion, we have examined such corporate records and other documents, including, but not limited to, the following documents: (a) the currently effective articles of incorporation and bylaws of the Issuer (b) corporate minutes and written consents of the Issuer's board of directors and shareholders; and (c) such other corporate records and other as were necessary and provided by the Issuer management for purposes of this letter.

In all such examinations and in giving our opinion, we have assumed the genuineness of all signatures (including those delivered by facsimile or electronic mail in "PDF" format), the legal capacity and competency at all relevant times of all natural persons signing any documents, the authenticity of all documents submitted to us as originals, the conformity to authentic original documents of all documents submitted to us as certified, authenticated, conformed, notarized, photostatic or facsimile copies and the authenticity of the originals of such certified, authenticated,

conformed, notarized, photostatic or facsimile copies. We have also assumed that (a) all facts set forth in the official public records, certificates, and documents supplied by public officials or otherwise conveyed to us by public officials are complete, true and accurate and (b) all facts set forth in the certificates supplied by the representatives of the Issuer are complete, true, and accurate. We express no opinion as to the validity of any of the assumptions, for or content of any financial or statistical data contained in the Information (as defined below).

Where we render an opinion herein with respect to the existence or absence of facts or circumstances and such opinion is qualified by the expression “to our knowledge” or words to like effect, it is based solely on: (i) the actual knowledge of the current partners and employees of our law firm learned during the course of representing the Issuer; (ii) a review of any executed certificate of representatives of the Issuer referred to above covering such matters; and (iii) such other investigation, if any, as we specifically set forth herein. We have not undertaken any other investigation.

On March 25, 2016, the Issuer posted on OTC Disclosure and News Service its Annual Report (the “Report”) pursuant to Rule 15c2-11(a)(5), which Report contained the Issuer’s Financial Statements for the Year Ended December 31, 2015, including its unaudited consolidated balance sheet, related statement of income, consolidated statement of cash flow and consolidated statement of stockholders’ equity (the “Financial Statements”). The Report and the Financial Statements are collectively referred to as “Information.” We have reviewed such documents in connection with our preparation of this letter.

Based on the examination set forth above, we are of the opinion that the Information (i) constitutes “adequate current public information” concerning the Issuer’s common stock, par value \$0.00001 per shares (the “Securities”) and the Issuer and “is available” within the meaning of Rule 144(c)(2) under the Securities Act, (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the “Exchange Act”), (iii) complies as to form with the OTC Markets Group’s OTC Pink Disclosure Guidelines, which are located on the Internet at [www.otcmarkets.com](http://www.otcmarkets.com), and (iv) has been posted through the OTC Disclosure and News Service.

The Issuer’s Financial Statements were prepared by Eugene Chiaramonte III, who is the Issuer’s Chief Operating Officer and Secretary. Mr. Chiaramonte III has a Bachelors of Science in Business Administration with a concentration in accounting and finance and has previously provided accounting services for other publicly traded companies. The Issuer has represented to us that the Financial Statements were prepared in accordance with Generally Accepted Accounting Principles.

The Issuer's transfer agent is Interstate Transfer Company with an address of 1671 Roycroft Place, Suite C, Salt Lake City, Utah 84124, and is registered with the SEC. The method used to confirm the number of outstanding shares of the Issuers stock as set forth in the Report was through receipt of written confirmation from the transfer agent as to the number of outstanding shares.

We have (i) personally met with management and a majority of the directors of the Issuer, (ii) reviewed the Information published by the Issuer on the OTC Disclosure and News Service, and (iii) discussed the Information with management and a majority of directors of the Issuer.

To the best of our knowledge, after inquiry of management and the directors of the Issuer, neither the Issuer, any 5% holder, nor our law firm is currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.

OTC Markets Group Inc. is entitled and authorized to rely on this letter in determining whether the Issuer has made adequate information publicly available within the meaning of 144(c)(2) under the Securities Act. No person or entity other than OTC Markets Group Inc. is entitled to rely on this letter, but permission is granted to OTC Markets Group Inc. to publish this letter in the OTC Disclosure and News Service for viewing by the public and regulators. This opinion speaks only as of the date above written. We assume no duty to update, revise, or supplement this opinion or to communicate with you with respect to any change in law that comes to our attention hereafter.

Very truly yours,

/s/ Indeglia & Carney, LLP